Browsing by Author "Dane, Faysal"

Now showing 1 - 8 of 8

Association of Age with Breast Cancer Clinical and Pathological Factors: Analysis of Turkish National Breast Cancer Registry
(2015) Benekli, Mustafa; Altundag, Kadri; Dumanli, Esra; Isikdogan, Abdurrahman; Karaoglu, Aziz; Tekin, Salim Basol; Oksuzoglu, Berna; Kocer, Murat; Sevinc, Alper; Boruban, Melih Cem; Turna, Hande; Uslu, Ruchan; Ozyilkan, Ozgur; Yalcin, Bulent; Coskun, Ugur; Kilickap, Saadettin; Dogu, Gamze Gokoz; Ozturk, Banu; Gumus, Mahmut; Buyukberber, Suleyman; Uncu, Dogan; Kara, Oguz; Aliustaoglu, Mehmet; Ozkan, Metin; Cicin, Irfan; Elkiran, E. Tamer; Dane, Faysal; Avci, Nilufer; Ulas, Arife; Ozdemir, Feyyaz; Kaya, Ali Osman
Geographic Variations of Clinical Characteristics in Breast Cancer: Analysis of Turkish National Breast Cancer Registry
(2015) Kilickap, Saadettin; Altundag, Kadri; Dumanli, Esra; Gumus, Mahmut; Uslu, Ruchan; Ozyilkan, Ozgur; Yalcin, Bulent; Kara, Oguz; Dogu, Gamze Gokoz; Ozturk, Banu; Kaya, Ali Osman; Aliustaoglu, Mehmet; Uncu, Dogan; Ozdemir, Feyyaz; Cicin, Irfan; Ozkan, Metin; Kocer, Murat; Turna, Hande; Buyukberber, Suleyman; Benekli, Mustafa; Coskun, Ugur; Karaoglu, Aziz; Tekin, Salim Basol; Dane, Faysal; Avci, Nilufer; Ulas, Arife; Oksuzoglu, Berna; Sevinc, Alper; Boruban, Melih Cem
Metastatic Cutaneous Melanoma Epidemiological Registry in Turkey: A Preliminary Evaluation of Diagnosis and Treatment Approaches
(2021) Karaca, Burcak S.; Sezer, Ahmet; Goksu, Sezgin S.; Cicin, Irfan; Erdem, Dilek; Cubukcu, Erdem; Dane, Faysal; Hacibekiroglu, Ilhan; Oksuzoglu, Berna; Alnigenis, Ebru; Ulay, Esat; Celik, Ismail
A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey - NOTES study
(2018) Ozyilkan, Ozgur; Yalcin, Suayib; Yildiz, Ramazan; Dane, Faysal; Karaoglu, Aziz; Oksuzoglu, Berna; Sevinc, Alper; Ozdemir, Feyyaz; Turna, Hande; Uslu, Ruchan; Ulay, Esat; 0000-0001-8825-4918; 29551901; AAD-2817-2021
Introduction: The introduction of targeted therapies in renal cell carcinoma has significantly improved its prognosis and treatment outcomes in recent years. Such treatment options are targeted therapies of the vascular endothelial growth factor (VEGF) pathway and the mammalian target of the rapamycin pathway. With the use of tyrosine kinase inhibitors (TKIs) and mammalian target of the rapamycin inhibitors, overall survival has increased up to 2 years. In Turkey, due to applicable reimbursement conditions for patients with metastatic renal cell carcinoma (mRCC), interferon use is mandated as a first-line treatment, thus providing information on the use of everolimus only after initial interferon and second-line VEGF-targeted treatments such as VEGF-TKI. Patients and methods: To provide a first real-life data set in Turkey, we conducted a prospective, non-interventional, observational study and assessed the efficacy and safety of everolimus after two lines of treatment including interferon. A total of 100 patients with histologically confirmed mRCC were enrolled in the study from 11 centers between June 2012 and March 2014 (70 males and 30 females). Efficacy was assessed on the basis of progression-free survival and overall survival; safety of everolimus was assessed on the basis of adverse event occurrence. Results: The study results showed that the median progression-free survival with everolimus treatment was 8.1 months (95% CI: 5.1-11.1) and the median overall survival was 17.6 months (95% CI: 10.1-25.1), thus indicating a better overall response based on survival durations than those from the randomized Phase III REnal Cell cancer treatment with Oral RAD001 given Daily study results (4.9 and 14.8 months, respectively). Conclusion: The study showed that everolimus treatment is a safe and effective treatment option in the treatment of mRCC after VEGF-TKI, with an acceptable safety and tolerability profile in real-life settings.
A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study) A Turkish Oncology Group Study
(2021) Abali, Huseyin; Yalcin, Suayib; Onal, Huseyin C; Dane, Faysal; Oksuzoglu, Berna; Ozdemir, Nuriye; Mertsoylu, Huseyin; Artac, Mehmet; Camci, Celaletdin; Karabulut, Bulent; Basal, Fatma B.; Budakoglu, Burcin; Sendur, Mehmet A. N.; Goktas, Burce; Ozdener, Fatih; Baygul, Arzu; 33979100
Background: Trastuzumab prolonged the overall survival in patients with advanced gastric cancer with human epidermal growth factor receptor 2 (HER2) overexpression in combination with chemotherapy. In this phase II open-label prospective study, the tolerability and safety of trastuzumab with chemotherapy, and chemoradiotherapy for curatively resected patients with HER2-positive gastric carcinoma was investigated. Methods: The patients with HER2-positive gastric, or gastroesophageal junction adenocarcinoma, after gastrectomy plus D2 dissection, were included. They received 3 cycles of oxaliplatin (100 mg/m(2) intravenously day 1) plus capecitabine (850 mg/m(2) orally days 1 to 14), trastuzumab (8 mg/kg intravenously day 1 in cycle 1, 6 mg/kg thereafter) every 21 days, followed by chemoradiotherapy. Trastuzumab was given for 1 year. Results: Of the 212 patients screened, 35 were eligible, and 34 were treated. The median age was 56 years (minimum to maximum: 35 to 75 y), male patients constituted 73.5% (n=25), and 33 (97.1%) had gastric adenocarcinoma. R0 resection was performed in 30 (88.2%). The majority (26, 61.7%) were in stage III disease. Most of the adverse events were grade I/II, the most frequent grade III side effects were nausea (3, 8.8%), vomiting (3, 8.8%), diarrhea (2, 5.9%), and weight loss (n=2, 5.9%). Two patients died during the first 3 cycles of chemotherapy and chemoradiotherapy; 1 secondary to pulmonary thromboembolism, and the other due to cerebral ischemia. After excluding 2 with early progression and 1 consent withdrawal, of the remaining 31 patients, 28 (90.3%) were able to complete the chemotherapy and chemoradiotherapy part of the trial. After the 25 months follow-up period, 21 patients (61.8%) were alive. Overall survival at 12 and 24 months was 75.0% and 58.0%, while disease-free survival at 12 and 24 months was 65.7% and 55.0%, respectively. Conclusions: Trastuzumab in combination with capecitabine, oxaliplatin following chemoradiotherapy as the adjuvant therapy for gastric or gastroesophageal junction adenocarcinoma was considered as safe and tolerable. The frequency of HER2 overexpression in curatively resected patients is comparable to that in patients with metastatic disease
A Study of the Combination of Oxaliplatin, Capecitabine, and Herceptin (Trastuzumab) And Chemoradiotherapy in The Adjuvant Setting in Operated Patients with HER2+Gastric Or Gastro-Esophageal Junction Cancer (TOXAG Study).
(2016) Abali, Huseyin; Yalcin, Suayib; Onal, Huseyin Cem; Dane, Faysal; Oksuzoglu, Berna; Ozdemir, Nuriye; Mertsoylu, Huseyin; Artac, Mehmet; Camci, Celalettin; Karabulut, Bulent; Basal, Fatma Bugdayci; Budakoglu, Burcin; Sendur, Mehmet Ali Nahit; Goktas, Burce; Ozdener, Fatih; Calisgan, Arzu; https://orcid.org/0000-0002-1932-9784; M-9530-2014
A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemo-Radiotherapy in the Adjuvant Setting in Operated Patients with HER2+Gastric or Gastroesophageal Junction Cancer (TOXAG Study)
(2018) Abali, Huseyin; Yalcin, Suayib; Onal, Cem; Dane, Faysal; Oksuzoglu, Berna; Ozdemir, Nuriye; Mertsoylu, Huseyin; Artac, Mehmet; Camci, Celaletdin; Karabulut, Bulent; Basal, Fatma Bugdayci; Budakoglu, Burcin; Sendur, Mehmet Ali Nahit; Goktas, Burce; Ozdener, Fatih; Baygul, Arzu; HOC-5611-2023
Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study
(2020) Benekli, Mustafa; Gumus, Mahmut; Ozkan, Metin; Dane, Faysal; Elkiran, Emin T.; Cicin, Irfan; Sevinc, Alper; Aliustaoglu, Mehmet; Isikdogan, Abdurrahman; Meydan, Nezih; Oksuzoglu, Berna; Ozyilkan, Ozgur; Artac, Mehmet; Ozdemir, Feyyaz; Kilickap, Sadettin; 0000-0001-8825-4918; 33050804; AAD-2817-2021
Objective Cytokines have been the mainstay of treatment in metastatic renal cell cancer (mRCC) for decades before the introduction of tyrosine kinase inhibitors (TKIs), which dramatically changed the therapeutic landscape in these patients. This observational study was designed to evaluate use of TKIs in the treatment of cytokine-intolerant mRCC patients. Methods A total of 151 cytokine-intolerant mRCC patients who were treated with TKIs (sunitinib, pazopanib and sorafenib) were enrolled in this prospective, non-interventional, multi-center observational study at 16 oncology centers across Turkey. Mean (SD) age was 61.3 (11.1) years and 74.8% were males. Data on duration of TKI treatment was the primary outcome measure. Additionally, overall response rate (ORR), progression free survival (PFS), overall survival (OS) and safety data were recorded. Results Median duration of treatment was 8.2 months at a median follow up of 17.9 months. ORR and disease control rate were 12.5% and 70.8%, respectively. Median PFS and OS were 7.5 months (95%CI: 6.4-10.4) and 27.3 months (95%CI: 17.6-27.3) with no significant difference among three TKI agents in terms of treatment duration, ORR, PFS and OS. The most common adverse events excluding progression-which was the protocol requirement were diarrhea (13.6%), asthenia (13.6%) and hand-foot syndrome (12.6%). Dose modifications were required in 30.5% of the patients and 15% discontinued TKIs because of toxicity. Conclusions Our findings confirm the efficacy and safety profile of TKIs in the first-line treatment of mRCC patients intolerant to cytokine treatment. There was no significant difference among three TKI agents in terms of treatment duration, ORR, PFS and OS.